Q4 2016 EPS Estimates for Cambrex Corp. Lifted by First Analysis (CBM)
Cambrex Corp. (NYSE:CBM) – First Analysis increased their Q4 2016 earnings per share estimates for shares of Cambrex Corp. in a research report issued on Monday. First Analysis analyst S. Schwartz now forecasts that the brokerage will post earnings per share of $1.07 for the quarter, up from their previous estimate of $0.97. First Analysis currently has a “Overweight” rating and a $54.00 target price on the stock. First Analysis also issued estimates for Cambrex Corp.’s Q3 2017 earnings at $0.61 EPS.
Separately, Zacks Investment Research lowered shares of Cambrex Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 27th.
Shares of Cambrex Corp. (NYSE:CBM) opened at 50.95 on Wednesday. The firm has a market cap of $1.64 billion, a PE ratio of 25.76 and a beta of 1.81. Cambrex Corp. has a 52 week low of $29.50 and a 52 week high of $59.41. The company has a 50 day moving average of $43.61 and a 200 day moving average of $47.60.
Cambrex Corp. (NYSE:CBM) last announced its quarterly earnings data on Friday, November 4th. The company reported $0.47 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.06. Cambrex Corp. had a net margin of 13.24% and a return on equity of 24.11%. The firm earned $99.90 million during the quarter, compared to analysts’ expectations of $96.07 million. During the same quarter last year, the business earned $0.40 earnings per share. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year.
Hedge funds have recently added to or reduced their stakes in the stock. Aperio Group LLC raised its stake in Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock valued at $333,000 after buying an additional 221 shares during the last quarter. BlackRock Group LTD raised its stake in Cambrex Corp. by 5.0% in the first quarter. BlackRock Group LTD now owns 45,156 shares of the company’s stock valued at $1,987,000 after buying an additional 2,131 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Cambrex Corp. by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 812,239 shares of the company’s stock valued at $35,739,000 after buying an additional 2,588 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in Cambrex Corp. during the first quarter valued at $276,000. Finally, Panagora Asset Management Inc. raised its stake in Cambrex Corp. by 6.6% in the first quarter. Panagora Asset Management Inc. now owns 372,089 shares of the company’s stock valued at $16,372,000 after buying an additional 23,121 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Receive News & Stock Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related stocks with our FREE daily email newsletter.